Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Autolus Therapeutics Plc ADR (AUTL)

Autolus Therapeutics Plc ADR (AUTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,119,549
  • Shares Outstanding, K 265,926
  • Annual Sales, $ 1,700 K
  • Annual Income, $ -208,380 K
  • 60-Month Beta 1.90
  • Price/Sales 701.62
  • Price/Cash Flow N/A
  • Price/Book 7.12
Trade AUTL with:

Options Overview Details

View History
  • Implied Volatility 220.03% ( +104.79%)
  • Historical Volatility 59.78%
  • IV Percentile 99%
  • IV Rank 73.25%
  • IV High 290.43% on 10/17/23
  • IV Low 27.28% on 10/11/23
  • Put/Call Vol Ratio 0.50
  • Today's Volume 9
  • Volume Avg (30-Day) 225
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 3,299
  • Open Int (30-Day) 12,194

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.10
  • Number of Estimates 4
  • High Estimate 0.02
  • Low Estimate -0.28
  • Prior Year -0.23
  • Growth Rate Est. (year over year) +56.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.96 +2.78%
on 04/25/24
6.48 -37.19%
on 03/26/24
-2.26 (-35.70%)
since 03/25/24
3-Month
3.96 +2.78%
on 04/25/24
7.37 -44.78%
on 02/14/24
-1.88 (-31.60%)
since 01/25/24
52-Week
1.61 +152.80%
on 04/26/23
7.45 -45.37%
on 01/12/24
+2.34 (+135.26%)
since 04/25/23

Most Recent Stories

More News
Chart of the Day: Autolus Therapeutics - Effective Cancer Treatments

The Chart of the Day belongs to the oncology based biomedical company Autolus Therapeutics (AUTL) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical...

AUTL : 4.10 (-2.61%)
Autolus (AUTL) Selects Cardinal Health for Cell Therapy Supply

Autolus (AUTL) partners with Cardinal Health to bring next-generation CAR-T cell therapies to the market and revolutionize cancer treatment.

CAH : 104.26 (+0.70%)
OMCL : 27.07 (-1.31%)
SYNH : 42.98 (+0.02%)
AUTL : 4.10 (-2.61%)
Has Acasti Pharma (ACST) Outpaced Other Medical Stocks This Year?

Here is how Acasti Pharma (ACST) and Autolus Therapeutics PLC Sponsored ADR (AUTL) have performed compared to their sector so far this year.

ACST : 2.93 (+1.03%)
AUTL : 4.10 (-2.61%)
Is Alaunos Therapeutics (TCRT) Outperforming Other Medical Stocks This Year?

Here is how Alaunos (TCRT) and Autolus Therapeutics PLC Sponsored ADR (AUTL) have performed compared to their sector so far this year.

TCRT : 1.0708 (-9.25%)
AUTL : 4.10 (-2.61%)
Why Autolus Therapeutics Stock Is Crashing Today

Shares of Autolus Therapeutics (NASDAQ: AUTL) were crashing 35.9% as of 10:34 a.m. ET on Friday. The steep decline came after the biopharmaceutical company announced the price of a public stock offering...

AUTL : 4.10 (-2.61%)
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing

Palm Beach, FL – October 5, 2022 – FinancialNewsMedia.com News Commentary – Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality accounting for up to 4% of all...

ONCY : 1.1000 (+3.77%)
ONC.TO : 1.50 (+2.04%)
SNTI : 0.2750 (-2.10%)
INBX : 34.12 (-0.76%)
IMVT : 28.28 (-1.81%)
AUTL : 4.10 (-2.61%)
BMY : 44.62 (-8.68%)
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing

/PRNewswire/ -- FinancialNewsMedia.com News Commentary - Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality accounting...

BMY : 44.62 (-8.68%)
ONC.TO : 1.50 (+2.04%)
ONCY : 1.1000 (+3.77%)
SNTI : 0.2750 (-2.10%)
INBX : 34.12 (-0.76%)
IMVT : 28.28 (-1.81%)
AUTL : 4.10 (-2.61%)
Correction - Autolus Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022

In the previous version the link to register for the conference call was incorrect – this press release contains the correct link to register for the call,...

AUTL : 4.10 (-2.61%)
Autolus Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022

LONDON, July 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation...

AUTL : 4.10 (-2.61%)
Autolus Therapeutics to Participate in William Blair’s Biotech Focus Conference 2022, New York, July 12 – 13, 2022

LONDON, July 06, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation...

AUTL : 4.10 (-2.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies. The company's pipeline of product candidate involved in development for the treatment of haematological malignancies and solid tumours. Autolus Therapeutics plc is based in London,...

See More

Key Turning Points

3rd Resistance Point 4.94
2nd Resistance Point 4.77
1st Resistance Point 4.49
Last Price 4.10
1st Support Level 4.04
2nd Support Level 3.87
3rd Support Level 3.59

See More

52-Week High 7.45
Fibonacci 61.8% 5.22
Fibonacci 50% 4.53
Last Price 4.10
Fibonacci 38.2% 3.84
52-Week Low 1.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar